Table 4.
Patient clinicopathologic characteristics and comparison between surgical procedures in patients who underwent lobectomy, segmentectomy, and wedge resection for pN0 lung adenocarcinoma
| MLN Evaluation (+)a | MLN Evaluation (−)b | ||||
|---|---|---|---|---|---|
| Characteristic | Lobectomy (N=680) | Segmentectomy (N=123) | Wedge (N=91) | Wedge (N=161) | P |
| Age, years | 68 (61–75) | 68 (61–75) | 71 (65–76) | 70 (63–77) | 0.004 |
| Sex | |||||
| Female | 434 (64) | 85 (69) | 63 (69) | 101 (63) | 0.5 |
| Male | 246 (36) | 38 (31) | 28 (31) | 60 (37) | |
| Smoking | |||||
| Never | 144 (21) | 25 (20) | 9 (10) | 25 (16) | 0.14 |
| Former | 460 (68) | 81 (66) | 70 (77) | 116 (72) | |
| Current | 76 (11) | 17 (14) | 12 (13) | 20 (12) | |
| Pack-year index | 25 (4–50) | 25 (5–60) | 31 (15–56) | 36 (10–56) | 0.045 |
| CT tumor size, cm | 1.9 (1.5–2.4) | 1.7 (1.3–2.2) | 1.5 (1.2–1.9) | 1.5 (1.1–1.8) | <0.001 |
| Tumor SUVmax | 2.4 (1.3–4.4) | 2.4 (1.2–4.1) | 2.1 (1.2–2.9) | 1.9 (0.0–3.6) | 0.001 |
| T factor | |||||
| Tis | 1 (0) | 0 (0) | 0 (0) | 2 (1) | <0.001 |
| T1a | 129 (19) | 34 (28) | 22 (24) | 52 (32) | |
| T1a(mi) | 47 (7) | 17 (14) | 16 (18) | 26 (16) | |
| T1b | 304 (45) | 52 (42) | 34 (37) | 49 (30) | |
| T1c | 90 (13) | 6 (5) | 0 (0) | 2 (1) | |
| T2a | 97 (14) | 14 (11) | 19 (21) | 29 (18) | |
| T2b | 4 (1) | 0 (0) | 0 (0) | 0 (0) | |
| T3 | 8 (1) | 0 (0) | 0 (0) | 1 (1) | |
| Pathologic tumor size, cm | 1.7 (1.3–2.2) | 1.5 (1.1–2.0) | 1.3 (1.0–1.8) | 1.2 (1.0–1.6) | <0.001 |
| Invasive tumor size, cm | 1.4 (1.0–2.2) | 1.1 (0.7–1.5) | 1.0 (0.5–1.5) | 1.0 (0.6–1.4) | <0.001 |
| LVI | 269 (40) | 41 (33) | 26 (29) | 59 (37) | 0.2 |
| VPI | 96 (14) | 11 (9) | 19 (21) | 29 (18) | 0.051 |
| Necrosis (n=1041) | 80 (12) | 9 (7) | 5 (6) | 10 (6) | 0.053 |
| STAS | 263 (39) | 37 (30) | 34 (37) | 75 (47) | 0.043 |
| Predominant subtype | |||||
| AIS | 1 (0) | 0 (0) | 0 (0) | 2 (1) | 0.022 |
| MIA | 47 (7) | 17 (14) | 16 (18) | 26 (16) | |
| Lepidic | 55 (8) | 12 (10) | 12 (13) | 14 (9) | |
| Acinar | 308 (45) | 51 (41) | 31 (34) | 63 (39) | |
| Papillary | 110 (16) | 14 (11) | 10 (11) | 22 (14) | |
| Micropapillary | 36 (5) | 5 (4) | 6 (7) | 7 (4) | |
| Solid | 99 (15) | 17 (14) | 11 (12) | 23 (14) | |
| IMA | 22 (3) | 7 (6) | 5 (5) | 4 (2) | |
| Colloid | 2 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Histologic grade | |||||
| Low | 103 (15) | 30 (24) | 28 (31) | 42 (26) | 0.001 |
| Intermediate | 419 (62) | 64 (52) | 41 (45) | 85 (53) | |
| High | 158 (23) | 29 (24) | 22 (24) | 34 (21) | |
| Mutation status (n=890) | |||||
| Wild-type | 288 (49) | 49 (51) | 36 (49) | 61 (47) | 0.11 |
| EGFR | 133 (23) | 17 (18) | 7 (10) | 26 (20) | |
| KRAS | 168 (29) | 31 (32) | 30 (41) | 44 (34) | |
Data are no. (%) or median (25–75 percentile). AIS, adenocarcinoma in situ; CT, computed tomography; IMA, invasive mucinous adenocarcinoma; LVI, lymphovascular invasion; MIA, minimally invasive adenocarcinoma; MLN, mediastinal lymph node; ONM, occult lymph node metastasis; STAS, spread through air spaces; SUVmax, maximum standardized uptake value; VPI, visceral pleural invasion.
a
Pathologic evaluation of at least one MLN by either dissection or sampling.
b
No pathologic evaluation of MLNs.